Heather McArthur
Medical oncologist and researcher focused on breast cancer clinical trials, presenting detailed analyses of PARP inhibitors, immune checkpoint inhibitors, and TROP2-targeting antibody–drug conjugates for metastatic triple-negative breast cancer.
Best podcasts with Heather McArthur
Ranked by the Snipd community
Jan 30, 2026 • 28min
S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
Heather McArthur, a medical oncologist and breast cancer trialist, discusses PARP inhibitors, immune checkpoint inhibitors, and TROP2-targeting antibody–drug conjugates for metastatic triple-negative breast cancer. She outlines pivotal trials, next-generation agents, combinations of ADCs with PARP or PD-1 therapies, and practical toxicity management and sequencing considerations.
Nov 10, 2025 • 1h 58min
Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Dr Rita Nanda, expert in endocrine-resistant HR+ disease and targeted agents. Dr Harold J. Burstein, HER2 specialist with expertise in neoadjuvant and metastatic strategies. Dr Heather McArthur, authority on triple-negative disease and ADCs. Dr Matthew P. Goetz, investigator in HR+ and CDK4/6 research. They discuss genomic assays, sequencing of CDK4/6 and PI3K/AKT agents, ADC selection and toxicities, HER2 strategies, and ctDNA applications.
